107.79
1.22 (1.15%)
| Previous Close | 106.56 |
| Open | 107.95 |
| Volume | 265,193 |
| Avg. Volume (3M) | 1,057,471 |
| Market Cap | 7,483,577,344 |
| Price / Earnings (TTM) | 17.73 |
| Price / Earnings (Forward) | 1.51 |
| Price / Sales | 5.50 |
| Price / Book | 7.59 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 - 4 Nov 2024 |
| Profit Margin | 29.80% |
| Operating Margin (TTM) | 26.07% |
| Diluted EPS (TTM) | 6.09 |
| Quarterly Revenue Growth (YOY) | 22.50% |
| Quarterly Earnings Growth (YOY) | -34.10% |
| Total Debt/Equity (MRQ) | 60.41% |
| Current Ratio (MRQ) | 4.68 |
| Operating Cash Flow (TTM) | 440.98 M |
| Levered Free Cash Flow (TTM) | 263.30 M |
| Return on Assets (TTM) | 17.41% |
| Return on Equity (TTM) | 54.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Lantheus Holdings, Inc. | Bullish | Bullish |
Stockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 2.51% |
| % Held by Institutions | 101.02% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 175.00 (Redburn Atlantic, 62.36%) | Buy |
| Median | 137.00 (27.11%) | |
| Low | 125.00 (JMP Securities, 15.97%) | Buy |
| Average | 143.60 (33.23%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 106.48 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Redburn Atlantic | 03 Sep 2024 | 175.00 (62.36%) | Buy | 105.43 |
| JMP Securities | 01 Aug 2024 | 125.00 (15.97%) | Buy | 98.62 |
| Truist Securities | 01 Aug 2024 | 135.00 (25.25%) | Buy | 98.62 |
| B. Riley Securities | 25 Jul 2024 | 146.00 (35.45%) | Buy | 112.95 |
| Jones Trading | 19 Jul 2024 | 137.00 (27.10%) | Buy | 116.79 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Sep 2024 | Announcement | Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players |
| 15 Sep 2024 | Announcement | Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 |
| 05 Sep 2024 | Announcement | Lantheus Appoints Julie Eastland as New Board Member |
| 28 Aug 2024 | Announcement | Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference |
| 20 Aug 2024 | Announcement | Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 |
| 31 Jul 2024 | Announcement | Lantheus Reports Second Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |